A phase II study of sirolimus, tacrolimus and rabbit anti-thymocyte globulin as GVHD prophylaxis after unrelated-donor PBSC transplant

Bone Marrow Transplantation

Volumn 48, Issue 2, 2013, Pages 278-283

  Khaled, S K ^a   Palmer, J ^a   Stiller, T ^a   Senitzer, D ^b   Maegawa, R ^a   Rodriguez, R ^a   Parker, P M ^a   Nademanee, A ^a   Cai, J L ^a   Snyder, D S ^a   Karanes, C ^a   Osorio, E ^c   Thomas, S H ^a   Forman, S J ^a   Nakamura, R ^a  

^a Department of Hematology/HCT ^*  (United States)

^b HLA Laboratory   (United States)

^c Clinical Trials Office   (United States)

Author keywords

anti thymocyte globulin; PBSC transplantation; sirolimus; tacrolimus; unrelated donor

Indexed keywords

CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUDARABINE; MELPHALAN; METHOTREXATE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HUMAN; LIVER VENOOCCLUSIVE DISEASE; LOADING DRUG DOSE; MORNING DOSAGE; MORTALITY; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; REDUCED INTENSITY CONDITIONING; RELAPSE; SINGLE DRUG DOSE; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; UNRELATED DONORS;

ADULT; AGED; ANIMALS; ANTILYMPHOCYTE SERUM; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROSPECTIVE STUDIES; RABBITS; SIROLIMUS; TACROLIMUS; UNRELATED DONORS; YOUNG ADULT;

EID: 84873457670     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.175     Document Type: Article

References (26)

1. Gratwohl A, Hermans J, Apperley J, Arcese W, Bacigalupo A, Bandini G et al. Acute graft-versus-host disease: Grade and outcome in patients with chronic myelogenous leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation. Blood 1995; 86: 813-818
2. Lee SJ, Vogelsang G, Gilman A, Weisdorf DJ, Pavletic S, Antin JH et al. A survey of diagnosis, management, and grading of chronic GVHD. Biol Blood Marrow Transplant 2002; 8: 32-39
3. Cutler C, Kim HT, Hochberg E, Ho V, Alyea E, Lee SJ et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2004; 10: 328-336
4. Marty FM, Bryar J, Browne SK, Schwarzberg T, Ho VT, Bassett IV et al. Sirolimusbased graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: A cohort analysis. Blood 2007; 110: 490-500
5. Cutler C, Li S, Kim HT, Laglenne P, Szeto KC, Hoffmeister L et al. Mucositis after allogeneic hematopoietic stem cell transplantation: A cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant 2005; 11: 383-388
6. Rodriguez R, Nakamura R, Palmer JM, Parker P, Shayani S, Nademanee A et al. A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood 2010; 115: 1098-1105
7. Kessinger A, Smith DM, Strandjord SE, Landmark JD, Dooley DC, Law P et al. Allogeneic transplantation of blood-derived, T cell-depleted hemopoietic stem cells after myeloablative treatment in a patient with acute lymphoblastic leukemia. Bone Marrow Transplant 1989; 4: 643-646
8. Auberger J, Clausen J, Kropshofer G, Kircher B, Lindner B, Nachbaur D. Allogeneic bone marrow versus peripheral blood stem cell transplantation: A long-term retrospective single-centre analysis in 329 patients. Eur J Haematol 2011; 87: 531-538
9. Remberger M, Ringden O, Blau IW, Ottinger H, Kremens B, Kiehl MG et al. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood 2001; 98: 1739-1745
10. Eapen M, Logan BR, Confer DL, Haagenson M, Wagner JE, Weisdorf DJ et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant 2007; 13: 1461-1468
11. Elmaagacli AH, Basoglu S, Peceny R, Trenschel R, Ottinger H, Lollert A et al. Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia. Blood 2002; 99: 1130-1135
12. Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR et al. Increased incidence of chronic graft-versus-host disease (GVHD) and no survival advantage with filgrastim-mobilized peripheral blood stem cells (PBSC) compared to bone marrow (BM) transplants from unrelated donors: Results of blood and marrow transplant clinical trials network (BMT CTN) protocol 0201, a phase III, prospective, randomized trial. ASH 2011; 118: 1
13. Rodriguez R, Nademanee A, Palmer JM, Parker P, Nakamura R, Snyder D et al. Thymoglobulin, CYA and mycophenolate mofetil as GVHD prophylaxis for reduced-intensity unrelated donor hematopoietic cell transplantation: Beneficial effect seen on chronic GVHD. Bone Marrow Transplant 2010; 45: 205-207
14. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304
15. Shulman HM, Sale GE, Lerner KG, Barker EA, Weiden PL, Sullivan K et al. Chronic cutaneous graft-versus-host disease in man. Am J Pathol 1978; 91: 545-570
16. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, 9 August 2006. Available at: Http://ctep.cancer. gov/ protocolDevelopment/electronic-applications/docs/ctcaev3.pdf
17. Breslow NE, Day NE. Statistical methods in cancer research: Volume II, the design and analysis of cohort studies. IARC Sci Publ 1987; 82: 1-406
18. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999; 18: 695-706
19. Rosenthal J, Pawlowska A, Bolotin E, Cervantes C, Maroongroge S, Thomas SH et al. Transplant-associated thrombotic microangiopathy in pediatric patients treated with sirolimus and tacrolimus. Pediatr Blood Cancer 2011; 57: 142-146
20. Ramsay NK, Kersey JH, Robison LL, McGlave PB, Woods WG, Krivit W et al. A randomized study of the prevention of acute graft-versus-host disease. N Engl J Med 1982; 306: 392-397
21. Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001; 98: 2942-2947
22. Bacigalupo A. Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: Efficacy and side effects. Bone Marrow Transplant 2005; 35: 225-231
23. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956
24. Rosenbeck LL, Kiel PJ, Kalsekar I, Vargo C, Baute J, Sullivan CK et al. Prophylaxis with sirolimus and tacrolimus /- antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010; 17: 916-922
25. George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I et al. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transpl Infect Dis 2010; 12: 322-329
26. Reddy N, Rezvani K, Barrett AJ, Savani BN. Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients. Biol Blood Marrow Transplant 2011; 17: 591-597